{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:10Z","timestamp":1793924830724,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001732","name":"Danish National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacadv.2026.102738","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:12:28Z","timestamp":1776460348000},"page":"102738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy"],"prefix":"10.1016","volume":"5","author":[{"given":"Nicholas","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-9761","authenticated-orcid":false,"given":"Fardad","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik B.","family":"Schelbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4104-909X","authenticated-orcid":false,"given":"Elisavet","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Reese-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacadv.2026.102738_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"15","key":"10.1016\/j.jacadv.2026.102738_bib2","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.02.018","article-title":"Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction","volume":"67","author":"Rommel","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102738_bib3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102738_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1532-429X-15-92","article-title":"Myocardial T1 mapping and extracellular volume quantification: a Society for cardiovascular magnetic resonance (SCMR) and CMR working group of the European Society of cardiology consensus statement","volume":"15","author":"Moon","year":"2013","journal-title":"J Cardiovasc Magnet Reson"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102738_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1161\/CIRCIMAGING.112.000192","article-title":"Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume","volume":"6","author":"Miller","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102738_bib6","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","article-title":"Circulating biomarkers of myocardial fibrosis: the need for a reappraisal","volume":"65","author":"Lopez","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102738_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024753","article-title":"MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assay","volume":"6","author":"Veidal","year":"2011","journal-title":"PLoS One"},{"issue":"10-11","key":"10.1016\/j.jacadv.2026.102738_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","article-title":"A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen","volume":"43","author":"Barascuk","year":"2010","journal-title":"Clin Biochem"},{"issue":"7","key":"10.1016\/j.jacadv.2026.102738_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/liv.15270","article-title":"An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution","volume":"42","author":"Pehrsson","year":"2022","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102738_bib10","doi-asserted-by":"crossref","first-page":"Hep32","DOI":"10.2217\/hep-2020-0030","article-title":"Endotrophin, a pro-peptide of type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma","volume":"8","author":"Leeming","year":"2020","journal-title":"Hepat Oncol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102738_bib11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/1756-185X.13804","article-title":"Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis","volume":"23","author":"Kubo","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102738_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102738_bib13","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.3390\/jcm9103216","article-title":"Biopsy-controlled non-invasive quantification of collagen type VI in kidney transplant recipients: a post-hoc analysis of the MECANO trial","volume":"9","author":"Yepes-Calder\u00f3n","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102738_bib14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/ndt\/gfab163","article-title":"Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis","volume":"37","author":"Sparding","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102738_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028134","article-title":"In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion","volume":"6","author":"Shi","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102738_bib16","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial","volume":"27","author":"Lewis","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102738_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10557-019-06876-y","article-title":"Pirfenidone in heart failure with preserved ejection fraction-rationale and design of the PIROUETTE trial","volume":"33","author":"Lewis","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102738_bib18","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102738_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144525","article-title":"Collagen type III and VI turnover in response to long-term immobilization","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2026.102738_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-40557-9","article-title":"Characterization of a novel assay for full-length endotrophin in heart failure with preserved ejection fraction","volume":"16","author":"Angeli","year":"2026","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102738_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G\u2217Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"issue":"11, Part 2","key":"10.1016\/j.jacadv.2026.102738_bib22","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jcmg.2019.04.025","article-title":"Why Clinicians should care about the cardiac interstitium","volume":"12","author":"Schelbert","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102738_bib23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.RES.70.5.1006","article-title":"Isolation, characterization, and localization of cardiac collagen type VI. Associations with other extracellular matrix components","volume":"70","author":"Bashey","year":"1992","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.jacadv.2026.102738_bib24","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0735-1097(89)90360-4","article-title":"Cardiac interstitium in health and disease: the fibrillar collagen network","volume":"13","author":"Weber","year":"1989","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102738_bib25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.yjmcc.2009.06.017","article-title":"Non-fibrillar collagens: key mediators of post-infarction cardiac remodeling?","volume":"48","author":"Shamhart","year":"2010","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102738_bib26","doi-asserted-by":"crossref","first-page":"H323","DOI":"10.1152\/ajpheart.00321.2005","article-title":"Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling","volume":"290","author":"Naugle","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102738_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCRESAHA.111.252734","article-title":"Absence of type VI collagen paradoxically improves cardiac function, structure, and remodeling after myocardial infarction","volume":"110","author":"Luther","year":"2012","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102738_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/clc.4960240413","article-title":"Collagen remodeling and cardiac dysfunction in patients with hypertrophic cardiomyopathy: the significance of type III and VI collagens","volume":"24","author":"Kitamura","year":"2001","journal-title":"Clin Cardiol"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102738_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102738_bib30","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/01.CIR.101.14.1729","article-title":"Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease","volume":"101","author":"Querejeta","year":"2000","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102738_bib31","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure","volume":"43","author":"L\u00f3pez","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jacadv.2026.102738_bib32","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","article-title":"Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study","volume":"112","author":"Izawa","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102738_bib33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho Carolyn","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102738_bib34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.matbio.2017.12.008","article-title":"Collagen VI disorders: insights on form and function in the extracellular matrix and beyond","volume":"71-72","author":"Lamand\u00e9","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.jacadv.2026.102738_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2024.06.003","article-title":"The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases","volume":"132","author":"Genovese","year":"2024","journal-title":"Matrix Biol"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102738_bib36","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200091","article-title":"Endotrophin, a collagen VI formation-derived peptide, in heart failure","volume":"1","author":"Chirinos","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102738_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/endrev\/bnad036","article-title":"Endotrophin, a key marker and driver for fibroinflammatory disease","volume":"45","author":"Henriksen","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jacadv.2026.102738_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1228232","article-title":"Endotrophin, a fibroblast matrikine, may be a driver of fibroblast activation in fibro-inflammatory diseases","volume":"10","author":"Reese-Petersen","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"19","key":"10.1016\/j.jacadv.2026.102738_bib39","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102738_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ Heart Fail"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26001596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26001596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:55:33Z","timestamp":1793922933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26001596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2772963X26001596"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102738","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102738"}}